Loading...
XSHG
688566
, Last price  
Name

Jiangsu Jibeier Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHG:688566 chart
P/E
—
P/S
—
EPS
1.38
Vol. 1Y
—
Shs. 5Y
3.39%
Rev. 5Y
11.26%
Div Yld LY
—
Div Yld TTM
—
Revenues
965m
+7.63%
444,423,461452,325,276484,961,241542,519,478565,973,500509,693,982654,730,646860,933,244896,534,453964,930,489
Net income
259m
+17.94%
76,939,68477,523,96696,611,529112,914,545129,717,588114,901,346154,667,826219,087,897219,327,786258,668,188
CFO
251m
+16.71%
39,287,947111,658,25997,966,468115,448,696117,363,183150,556,993150,724,074159,500,018215,293,605251,273,766
Dividend
Oct 15, 20260.26 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical enterprise based in Zhenjiang, China, established in 2001. The company's core operations involve the research, development, manufacturing, and sales of a diverse range of pharmaceutical products, including chemical preparations, traditional Chinese medicine formulations, and active pharmaceutical ingredients (APIs). Its product portfolio addresses various health concerns, offering solutions for boosting white blood cell counts, enhancing the immune system, treating joint-related ailments, managing high blood pressure, combating ocular infections, alleviating bronchitis symptoms, and protecting liver function, among others. Additionally, Jiangsu Jibeier is actively engaged in developing new therapeutic drugs, with its pipeline focusing on treatments for conditions such as depression, oncology (tumors), and gastrointestinal disorders.
IPO date
May 18, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT